Cargando…

Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study

From March 1993 to February 1997, 43 eligible patients with inoperable stage IIIA (ten patients) and stage IIIB (33 patients), histologically confirmed NSCLC received 3 courses of the ICE combination (ifosfamide 1.5 g m(−2) and mesna 750 mg m(−2) two times a day, cisplatin 25 mg m(−2) and etoposide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scinto, A F, Ferraresi, V, Milella, M, Tucci, E, Santomaggio, C, Pasquali-Lasagni, R, Vecchio, M R Del, Campioni, N, Nardi, M, Cognetti, F
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362939/ https://www.ncbi.nlm.nih.gov/pubmed/10576661 http://dx.doi.org/10.1038/sj.bjc.6690803

Ejemplares similares

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma
por: Michelagnoli, M P, et al.
Publicado: (1999)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Valsalva-Like Retinopathy Secondary to Pancytopenia following Induction of Etoposide and Ifosfamide
por: Prinzi, Robert A., et al.
Publicado: (2015)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
por: Zhou, Ping, et al.
Publicado: (2015)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
por: Klaassen, U., et al.
Publicado: (1996)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
por: Horwich, A, et al.
Publicado: (2000)

A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).
por: Cerny, T., et al.
Publicado: (1989)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors
por: Villa, E, et al.
Publicado: (2001)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study
por: Mi, Mi, et al.
Publicado: (2020)

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study
por: Skinner, R, et al.
Publicado: (2000)

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma
por: HATAYAMA, YOSHIOMI, et al.
Publicado: (2013)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females
por: Zanetta, G, et al.
Publicado: (1999)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
por: Zhang, Yao, et al.
Publicado: (2021)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Carbon-ion radiotherapy for inoperable endometrial carcinoma
por: Irie, Daisuke, et al.
Publicado: (2018)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis
por: Saito, Shiro, et al.
Publicado: (2020)

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
por: Pelgrims, J, et al.
Publicado: (2000)

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
por: Bokemeyer, C., et al.
Publicado: (1996)

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)
por: Baldini, E, et al.
Publicado: (2001)

Intra-patient dose escalation in Ewing’s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review
por: Lewin, Jeremy, et al.
Publicado: (2013)

Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM.
por: Bonacci, R., et al.
Publicado: (1998)

Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer
por: Kang, Heeseok, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_72pse5jk4rftags2lsp0ajdltt